1 Retroactively restated to give effect to the October 19, 2021 reverse recapitalization.
SUPPLEMENTAL INFORMATION: | ||||||||||||||||
Three Months Ended
| Year Ended | |||||||||||||||
December 31, | December 31, | |||||||||||||||
2021 | 2020 | 2021 | 2020 | |||||||||||||
Stock-based compensation expenses included in: | ||||||||||||||||
Net revenues | $ | — | $ | 331 | $ | 163 | $ | 331 | ||||||||
Research and development | 4,926 | 302 | 6,624 | 477 | ||||||||||||
Selling, general and administrative | 21,713 | 182 | 34,617 | 228 | ||||||||||||
Total stock-based compensation expense | $ | 26,639 | $ | 815 | $ | 41,404 | $ | 1,036 | ||||||||
Research and development includes: | ||||||||||||||||
Amortization of acquisition-related intangible assets | $ | 87 | $ | 83 | $ | 361 | $ | 167 | ||||||||
Other acquisition-related expenses included in: | ||||||||||||||||
Research and development | $ | 500 | $ | — | $ | 500 | $ | — | ||||||||
Selling, general and administrative | 1,795 | — | 1,795 | — | ||||||||||||
Total other acquisition-related expenses | $ | 2,295 | $ | — | $ | 2,295 | $ | — | ||||||||